Laura Hamill - 06 Jan 2023 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Reporting relationship: Director
Issuer ticker: ANAB
Reported as of: 06 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jan 2023, 18:07:00 UTC
Prior SEC filing: 15 Nov 2022
Next SEC filing: 17 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Eric Loumeau, Attorney-in-Fact

Key filing fact

Laura Hamill filed Form 4 for ANAPTYSBIO, INC (ANAB) on 10 Jan 2023.

Key facts

This page summarizes Laura Hamill's Form 4 filing for ANAPTYSBIO, INC (ANAB).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Jan 2023, 18:07.

Change

Previous filing in this sequence was filed on 15 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANAB transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +10,600
Change %
Price: $0.000000
Shares after: 10,600
Date: 06 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,600
Exercise price: $23.23
Footnotes: F1

ANAB transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +3,900
Change %
Price: $0.000000
Shares after: 3,900
Date: 06 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,900
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F2

Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Footnote F3

The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.